



Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

March 13, 2023

- Presentation to be webcast on www.exelixis.com -

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2023-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. PT.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow [@ExelixisInc](https://twitter.com/ExelixisInc) on Twitter, like [Exelixis, Inc.](https://www.facebook.com/Exelixis.Inc) on Facebook and follow [Exelixis](https://www.linkedin.com/company/exelixis) on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230313005670/en/): <https://www.businesswire.com/news/home/20230313005670/en/>

Investors Contact:

Varant Shirvanian
Associate Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com

Media Contact:

Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com

Source: Exelixis, Inc.